Aravo CCO Dave Rusher discusses the risk of third-party AI usage at pharma companies.
Dave Rusher
Advertisement
Dave Rusher is CCO at Aravo.
Articles by Dave Rusher
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Releases Open Letter Warning of Potential Safety Risks for Compounded Tirzepatide Plus Vitamin B12
2
Pharmaceutical Executive Daily: Senate Democrats Seeking Information on MFN Pharma Deals
3
Agentic AI and the Future of Commercial Excellence in Life Sciences
4
Navigating Complexity in Emerging Biotech: Innovations, Integrations, and Initial Hurdles
5